← Patent-cliff monitor small molecule VENCLEXTA VENETOCLAX
Loss of exclusivity September 2033 latest FDA-listed patent expiry
Company AbbVie Inc. → See this company's full patent-cliff portfolio Drug detail Brand name VENCLEXTA Active ingredient VENETOCLAX Strength 100MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2016 Marketing status RX
Listed patents Patent Expires Type 9539251 September 2033 use U-2538 11413282 September 2033 use U-3412 11590128 September 2033 use U-3548 10993942 September 2033 use U-3114 11110087 September 2033 use U-3223 11369599 May 2032 product 8722657 January 2032 substance 10730873 November 2031 substance 8546399 June 2031 substance, product 9174982 May 2030 use U-2323
Regulatory exclusivity Code Expires ODE-239 May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.